Lisa Keong

Ms. Lisa Keong

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2025 in Nature Medicine
Verified
Journal Article
Closed access
MRMelissa A. Rolfes
Melissa A. Rolfes
KKKrista Kniss
Krista Kniss
MKMarie K. Kirby
Marie K. Kirby
SGShikha Garg
Shikha Garg
KRKatie Reinhart
Katie Reinhart
SOSonja J. Olsen
Sonja J. Olsen

6 January 2025 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
JCJessie R Chung
Jessie R Chung
APAshley M Price
Ashley M Price
RZRichard Zimmerman
Richard Zimmerman
KGKrissy Moehling Geffel
Krissy Moehling Geffel
SHStacey L House
Stacey L House
BFBrendan Flannery
Brendan Flannery
Background: The 2023–2024 US influenza season was characterized by a predominance of A(H1N1)pdm09 virus circulation with cocirculation of A(H3N2) and B/Victoria viruses. We estimated vaccine effectiveness (VE) in the United States against mild-to-moderate medically attended influenza illness in the 2023–2024 season. Methods: We enrolled outpatients aged ≥8 months with acute respiratory illness in 7 states. Respiratory specimens were tested for influenza type/subtype by reverse-transcriptase polymerase chain reaction. Influenza VE was estimated with a test-negative design comparing odds of testing positive for influenza among vaccinated versus unvaccinated participants. We estimated VE by virus subtype/lineage and A(H1N1)pdm09 genetic subclades. Results: Among 6629 enrolled patients, 1780 (27%) tested positive for influenza, including 806 with A(H1N1)pdm09, 567 with B/Victoria, and 328 with A(H3N2). VE against any influenza illness was 44% (95% confidence interval, 36%–51%): 29% (15%–41%) against influenza A(H1N1)pdm09, 74% (65%–81%) against B/Victoria, and 30% (8%–47%) against A(H3N2). Statistically significant protection against any influenza was found for all age groups except adults aged 50–64 years. Lack of protection in this age group was specific to influenza A–associated illness. We observed differences in VE by birth cohort and A(H1N1)pdm09 virus genetic subclade. Conclusions: Vaccination reduced outpatient medically attended influenza overall by 44% and provided protection overall against circulating influenza A and B viruses. Serologic studies would help inform differences observed by age groups.

7 May 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
HDHan Di
Han Di
EPElizabeth Pusch
Elizabeth Pusch
JJJoyce Jones
Joyce Jones
NKNicholas A. Kovacs
Nicholas A. Kovacs
NHNorman Hassell
Norman Hassell
CDCharles Todd Davis
Charles Todd Davis
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into numerous lineages with unique spike mutations and caused multiple epidemics domestically and globally. Although COVID-19 vaccines are available, new variants with the capacity for immune evasion continue to emerge. To understand and characterize the evolution of circulating SARS-CoV-2 variants in the U.S., the Centers for Disease Control and Prevention (CDC) initiated the National SARS-CoV-2 Strain Surveillance (NS3) program and has received thousands of SARS-CoV-2 clinical specimens from across the nation as part of a genotype to phenotype characterization process. Focus reduction neutralization with various antisera was used to antigenically characterize 143 SARS-CoV-2 Delta, Mu and Omicron subvariants from selected clinical specimens received between May 2021 and February 2023, representing a total of 59 unique spike protein sequences. BA.4/5 subvariants BU.1, BQ.1.1, CR.1.1, CQ.2 and BA.4/5 + D420N + K444T; BA.2.75 subvariants BM.4.1.1, BA.2.75.2, CV.1; and recombinant Omicron variants XBF, XBB.1, XBB.1.5 showed the greatest escape from neutralizing antibodies when analyzed against post third-dose original monovalent vaccinee sera. Post fourth-dose bivalent vaccinee sera provided better protection against those subvariants, but substantial reductions in neutralization titers were still observed, especially among BA.4/5 subvariants with both an N-terminal domain (NTD) deletion and receptor binding domain (RBD) substitutions K444M + N460K and recombinant Omicron variants. This analysis demonstrated a framework for long-term systematic genotype to antigenic characterization of circulating and emerging SARS-CoV-2 variants in the U.S., which is critical to assessing their potential impact on the effectiveness of current vaccines and antigen recommendations for future updates.

21 April 2026 in Viruses
Verified
Journal Article
Open access
PDF file
JFJulia Frederick
Julia Frederick
KLKristine Lacek
Kristine Lacek
MWMatthew J Wersebe
Matthew J Wersebe
BSBo Shu
Bo Shu
LKLisa Keong
Lisa Keong
MKMarie K. Kirby
Marie K. Kirby
The first influenza A(H5N1) human case associated with the A(H5N1) dairy cattle outbreak in the United States was identified in April 2024. The U.S. CDC response to this outbreak was activated days later and remained active until July 2025. During this time, 70 human cases of influenza A(H5N1) were detected with a range of epidemiological links to sources of exposure. Next-generation sequencing (NGS) of human samples was an effectual mechanism for tracking and analyzing the outbreak evolution throughout the response. Due to the specimens’ importance and their variable physical quality, an assortment of laboratory methods was utilized including influenza segment-specific amplification, enrichment capture, short-read, and long-read sequencing. Combining these methods allowed for high-quality genomic data production with rapid turnaround times—typically 2 days from sample receipt to public database submission. By leveraging replicate sequencing, enrichment capture, and sequencing of diagnostic amplicons, valuable genomic data could be produced directly from human clinical specimens that would have normally been considered too weak for routine virologic surveillance sequencing. The resulting assemblies were characterized and analyzed by CDC and shared with local and state public health authorities to facilitate case investigations and risk assessment. These data were further used for phylogenetic analyses of viruses from human cases to investigate likely animal-to-human transmission events and identify clusters within the outbreak that might indicate trends in the types of exposures. Through the adaptable laboratory workflow and the rapid release of viral genomic data, the public health risk mitigation strategies could be evaluated and adjusted in real time.

1 August 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
MKMatthew W. Keller
Matthew W. Keller
LKLisa Keong
Lisa Keong
BRBenjamin L. Rambo-Martin
Benjamin L. Rambo-Martin
NHNorman Hassell
Norman Hassell
KLKristine Lacek
Kristine Lacek
JBJohn R. Barnes
John R. Barnes
The SARS-CoV-2 spike protein is a highly immunogenic and mutable protein that is the target of vaccine prevention and antibody therapeutics. This makes the encoding S-gene an important sequencing target. The SARS-CoV-2 sequencing community overwhelmingly adopted tiling amplicon-based strategies for sequencing the entire genome. As the virus evolved, primer mismatches inevitably led to amplicon drop-out. Given the exposure of the spike protein to host antibodies, mutation occurred here most rapidly, leading to amplicon failure over the most insightful region of the genome. To mitigate this, we developed SpikeSeq, a targeted method to amplify and sequence the S-gene. We evaluated 20 distinct primer designs through iterative in silico and in vitro testing to select the optimal primer pairs and run conditions. Once selected, periodic in silico analysis monitor primer conservation as SARS-CoV-2 evolves. Despite being designed during the Beta wave, the selected primers remain > 99% conserved through Omicron as of 2023-04-14. To validate the final design, we compared SpikeSeq data and National SARS-CoV-2 Strain Surveillance whole-genome data for 321 matching samples. Consensus sequences for the two methods were highly identical (99.998%) across the S-gene. SpikeSeq can serve as a complement to whole-genome surveillance or be leveraged where only S-gene sequencing is of interest. While SpikeSeq is adaptable to other sequencing platforms, the Nanopore platform validated here is compatible with low to moderate throughputs, and its simplicity better enables users to achieve accurate results, even in low resource settings.

22 July 2026 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Open access
PDF file
EMEileen A. Moran
Eileen A. Moran
MHMonique E. Hunter
Monique E. Hunter
JKJason G. Kralj
Jason G. Kralj
KGKristine Gierz
Kristine Gierz
JFJulia C. Frederick
Julia C. Frederick
MCMegan H. Cleveland
Megan H. Cleveland
In 2024, the US Centers for Disease Control and Prevention (CDC) and National Institute of Standards and Technology (NIST) initiated an interagency collaboration to bolster preparedness in the event of a pandemic scenario due to high pathogenicity avian influenza A(H5N1) clade 2.3.4.4b viruses that had been circulating in North America since 2021. Multiple spillover events into mammalian species, including an outbreak among dairy cattle and a surge in human cases, spurred the development of RNA reference materials to assist with new diagnostics development and validation. With input from CDC on sequences, NIST generated three synthetic RNA materials of A(H5N1) hemagglutinin, neuraminidase, and matrix proteins 1 and 2 gene segments. Here, we describe the development and characterization of these reference materials utilizing droplet digital reverse transcription polymerase chain reaction. Through this collaboration, we were able to rapidly provide quantified, homogeneous, stable, and epidemiologically relevant RNA reference materials to the public to aid new assay development and validation. Graphical abstract